CN¥101.85
1.85%
Shanghai, Oct 21, 03:00 pm CST. Closed.
ISIN
CNE1000048G6
Symbol
688331

Remegen Co-h Stock price

CN¥101.85
-23.15 18.52% 1M
-40.45 28.43% 6M
+24.06 30.93% YTD
+4.75 4.89% 1Y
+43.60 74.85% 3Y
+61.01 149.39% 5Y
+61.01 149.39% 10Y
+61.01 149.39% 20Y
Shanghai, Closing price Wed, Oct 21 2026
+1.85 1.85%
ISIN
CNE1000048G6
Symbol
688331
Industry

AI Insights on Remegen Co-h Insights AI Insights on Remegen Co-h

How does the company make money?
Who are the company’s main competitors?

Is Remegen Co-h a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,102 stocks worldwide.

Key metrics

Basic
Market capitalization
CN¥46.0b
Enterprise Value
CN¥41.2b
Net debt
positive
Cash
CN¥5.1b
Shares outstanding
564.5m
Valuation
P/E
9.6
P/S | estimate
5.7 | 6.2
EV/Sales | estimate
5.1 | 5.5
EV/FCF | ex SBC
9.4 | -
P/B
5.5
Financial Health
Equity Ratio
49.8%
Return on Equity
19.7%
ROCE
57.9%
ROIC
125.6%
Debt/Equity
0.0
Financials
Revenue | estimate
CN¥8.0b | CN¥7.5b
EBITDA
-
EBIT
CN¥4.9b
Net Income
CN¥5.8b
Free Cash Flow | ex SBC
CN¥4.4b | -
Growth
Revenue | estimate
286.2% | 129.2%
EBITDA
-
EBIT
575.5%
Net Income
612.1%
Free Cash Flow
655.7%
Margin
Gross
93.7%
EBITDA
-
EBIT
61.4%
Net
72.7%
Free Cash Flow | ex SBC
54.5% | -
More
EPS
CN¥10.4
FCF per Share
CN¥7.7
Short interest
-
Employees
3k
Rev per Employee
CN¥1.1m

Remegen Co-h Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Remegen Co-h forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a Remegen Co-h forecast:

Buy
85%
Hold
15%

Remegen Co-h Events

Upcoming Event
OCT
29
Q3 2026 Earnings Call
in 8 days

Financial data from Remegen Co-h

Jun '26
+/-
%
8,006 8,006
286% 286%
100%
- Direct Costs 508 508
38% 38%
6%
7,499 7,499
339% 339%
94%
- Selling and Administrative Expenses 1,624 1,624
16% 16%
20%
- Research and Development Expense 986 986
29% 29%
12%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 4,917 4,917
575% 575%
61%
Net Profit 5,822 5,822
612% 612%
73%

In millions CNY.

Don't miss a Thing! We will send you all news about Remegen Co-h directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

RemeGen Co Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Yantai, Shandong and currently employs 2,999 full-time employees. The company went IPO on 2020-11-09. RemeGen Co Ltd is a China-based company principally engaged in biopharmaceutical research, biopharmaceutical service, biopharmaceutical production and sale. The firm focuses on therapeutic antibody drugs such as antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company’s main products include telitacicept, disitamab vedotin, RC28-E and others. The firm's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The firm mainly operates its businesses in the domestic and overseas markets.

Head office China
CEO Mr. Fang
Employees 3,048
Website www.remegen.cn

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today